Background: Doxorubicin(Dox),an anthracycline antibiotic,is one of the most potent and widely used chemotherapeutic agents for various types of solid tumors.Unfortunately,its clinical application is tremendously restricted by the severe side effects of cardiotoxicity.Elimination or reduction of the cardiotoxicity of DOX without affecting its anticancer efficacy has become a research hotspot from bench to bedside.